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Abstract Extracellular nucleotide metabolism controls
thrombosis and inflammation and may affect degeneration
and calcification of aortic valve prostheses. We evaluated the
effect of different decellularization strategies on enzyme ac-
tivities involved in extracellular nucleotide metabolism. Por-
cine valves were tested intact or decellularized either by de-
tergent treatment or hypotonic lysis and nuclease digestion.
The rates of ATP hydrolysis, AMP hydrolysis, and adenosine
deamination were estimated by incubation of aorta or valve
leaflet sections with substrates followed by HPLC analysis.
We demonstrated relatively high activities of ecto-enzymes on
porcine valve as compared to the aortic wall. Hypotonic lysis/
nuclease digestion preserved >80 % of ATP and AMP hydro-
lytic activity but reduced adenosine deamination to <10 %.
Detergent decellularization completely removed (<5 %) all
these activities. These results demonstrate high intensity of
extracellular nucleotide metabolism on valve surface and in-
dicate that various valve decellularization techniques differ-
ently affect ecto-enzyme activities that could be important in
the development of improved valve prostheses.
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eNTPD ecto-nucleoside triphosphate diphosphohydrolase
HBSS Hank’s balanced salt solution
HPLC high performance liquid chromatography
NBTI S-(4-Nitrobenzyl)-6-thioinosine
PBS phosphate-buffered saline
SDS sodium dodecyl sulfate
TAVI transcatheter aortic valve implantation
VECs valvular endothelial cells
VICs valvular interstitial cells
Introduction
Calcific aortic valve disease (CAVD) is a progressive disorder
that increasingly afflicts the aging population. This disease
appears as a result of thickening and calcification of the aortic
valve leaflets and could have form of aortic sclerosis (in the
absence of obstruction in blood flow at the valve level) or
aortic stenosis (with obstruction to ventricular outflow) [1].
Left ventricular hypertrophy caused by severe aortic stenosis
is associated with sudden death, congestive heart failure, and
stroke [2]. Aortic sclerosis is evident in more than 25 % of
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patients over age 65, whereas aortic stenosis occurs in 2 to 5%
of the eldest patients, and it is the second most common indi-
cation for cardiac surgery [3, 4]. A surgical approach is the
method of choice for treatment for end-stage valvular dis-
eases. Aortic valve replacement (AVR) and transcatheter aor-
tic valve implantation (TAVI) have become routine procedures
with the number rising considerably over the last years [5, 6].
Mechanical or bioprosthetic valves are two general options
that exist for valve replacement procedures. Mechanical
valves display good structural durability but they are suscep-
tible to infection and are associated with the risk of thrombo-
embolic complications. For these patients, lifelong
anticoagulation therapy is required, associated with a high risk
of spontaneous bleeding and thromboembolism [7]. In the
field of biological grafts, cadaveric valves taken from human
donors (homografts) eliminate the need of anticoagulation and
have the best hemodynamic properties, but their availability is
limited. Other mammalian valves (xenografts), such as por-
cine aortic valves, are readily accessible and the risk of throm-
boembolic complications is minimal. However, xenografts
have to be processed in order to achieve sterility, alter immu-
nogenicity, and enhance their durability through alteration of
their physical properties [8]. Decellularization of xenogenic
material has become routine procedure to remove antigens
and nucleic acids while preserving extracellular matrix
(ECM) that provides a biomechanically efficient scaffold
[9]. The most common decellularization protocols include
steps, such as lysis of the cell membrane by hypotonic/
hypertonic treatment or detergent-based processing, followed
by enzymatic digestion, and removal of cellular debris by
isotonic washout [10–14]. To reduce potential transmission
of microbiological hazards, valves are sterilized by -irradia-
tion since glutaraldehyde sterilization has been associated
with scaffold destruction [15]. Despite optimal hemodynam-
ics and resistance to infection, the major problem of
bioprosthetic valve durability is progressive degeneration
due to chronic inflammation and calcification [16, 17].
Our previous studies identified extracellular adenosine tri-
phosphate (ATP) as a potent regulator of osteoblast differen-
tiation in human valve interstitial cells [18]. Also, other au-
thors reported that ATP and activi ty of valvular
ectonucleotidases engaged in its metabolism could play a sub-
stantial role in the development and progression of CAVD
[19]. Moreover, extracellular ATP exerts pro-inflammatory
and pro-aggregatory actions that promote pathological pro-
cesses within valves and vessel wall [20, 21]. In addition to
ATP (which acts through P2 receptors), its breakdown prod-
uct—adenosine, also displays many regulatory functions via
P1 receptors, widely distributed in the cardiovascular system.
The spectrum of extracellular adenosine activities is mostly
protective against inflammation, foam cells accumulation, or
platelets aggregation—disorders that initiate aortic sclerosis
and atherosclerosis [22–24]. Moreover, adenosine is also
recognized as a regulator of calcification within the cardiovas-
cular system, since lack of the main adenosine-producing en-
zyme in vasculature is manifested by arterial calcification
[25]. This statement is supported by our previous results indi-
cating that adenosine protected valvular interstitial cells
(VICs) against osteoblast differentiation [18]. However, the
role of adenosine and enzymes responsible for its metabolism
in CAVD still raises controversy [26]. Nonetheless, our stud-
ies showed that native intact aortic valves are rich in
membrane-bound enzymes that catalyze metabolism of extra-
cellular ATP to adenosine, what is essential in maintaining the
balance between these regulatory molecules [27]. The most
important role in extracellular nucleotide cascade, on the sur-
face of heart valves, is played by ecto-nucleoside triphosphate
diphosphohydrolase 1 (eNTPD-1/CD39), which hydrolyzes
ATP to adenosine monophosphate (AMP) through adenosine
diphosphate (ADP), ecto-5′-nucleotidase (e5′NT/CD73),
which degrades AMP to adenosine and adenosine deaminase
(eADA), which is responsible for extracellular adenosine de-
amination [28, 29].
This study compared the activities of enzymes involved in
extracellular nucleotide metabolism in the valve leaflets and
aortic wall and evaluated how different methods used for
decellularization of xenograft valves affect these activities.
Methods
Valve Preparation
Fresh porcine aortic valves (n=8) and ascending aorta frag-
ments (n=4) were obtained from 1-year-old pig hearts from a
local slaughterhouse, placed into ice-cold physiologic salt so-
lution and transported to the laboratory on ice within 1 h of
harvest. Aortic valve leaflets were dissected from the aortic
valve conduit and divided into 0.2-cm2 sections. Similar sec-
tions were obtained from aortas. These sections were washed
in Hank’s Balanced Salt Solution (HBSS) and used in exper-
iments to study native ecto-enzyme activities or used for pro-
cessing. The first processing method was carried out by hypo-
tonic lysis in deionized water, followed by DNAseI/RNAseA
digestion, as previously described [30]. Subsequently, valves
were washed, cryopreserved in 10 % DMSO/10 % fetal bo-
vine serum in DMEM and subjected to sterilization by 25–
40 kGy of γ-radiation in dry ice. A second processing method
applied previously described decellularization procedure
based on incubation of valves with 0.1 % sodium dodecyl
sulfate (SDS) with 0.1 % EDTA in 10 mM Tris–HCl,
pH 8.0 (48 h), followed by nuclease digestion, cryopreserva-
tion in DMSO, and sterilization using γ-radiation [31–33].
Prior to analysis, valves were warmed, thawed by immersing
the valve package in 40 °C water, and DMSOwas washed out
by rinsing in phosphate-buffered saline (PBS).
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Analysis of Extracellular Nucleotide Catabolism Enzymes
Intact aorta fragments, native, and processed aortic valve leaf-
lets were incubated in 1 ml of HBSS with substrates for ex-
tracellular enzymes. Adenosine, ATP, and AMP at final con-
centration of 50 μMwere sequentially added to 1 ml of HBSS
with medium exchange after each substrate. An inhibitor of
adenosine deaminase-erythro-9-(2-hydroxy-3-nonyl) adenine
(EHNA) was present at 5 μM concentration during incubation
with ATP and AMP to block conversion of adenosine to ino-
sine. To ensure that evaluated activities originate exclusively
from the action of extracellular enzymes, part of the experi-
ments were conducted with the addition of the nucleoside
transport inhibitor: S-(4-Nitrobenzyl)-6-thioinosine (NBTI).
Samples were collected after 0, 5, 15, and 30 min of incuba-
tion at 37 °C and then directly injected onto HPLC. Concen-
trations of nucleotides and nucleosides were measured by
reversed-phase HPLC according to the method described ear-
lier [34]. The rates of ATP hydrolysis, AMP hydrolysis, and
adenosine deamination were calculated from linear phase of
the reaction and normalized to the surface area.
Statistical Methods
Values are presented as mean±SEM. Statistical analysis was
performed using paired Student’s t test to compare two groups
or one-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison test to compare more than two
groups (InStat software, GraphPad, San Diego). A p value
<0.05 was considered as significant difference.
Results
In order to examine the extracellular adenine nucleotide ca-
tabolism, the rates of ATP and AMP hydrolysis as well as
adenosine degradation were tested on the native valve surface.
Intact porcine aortic valve leaflets were characterized by two
times higher activities of enzymes engaged in ATP (Fig. 1)
and AMP hydrolysis (Fig. 2) in comparison to the aortic wall.
Adenosine deaminase activity was approximately 2.5-fold
lower on the surface of aortic valve than in aorta (Fig. 3). This
demonstrates the special role of extracellular enzymes en-
gaged in nucleotide metabolism in the aortic valve. Observed
ecto-enzymes pattern, determined by the fast rate of nucleo-
tides hydrolysis and slowed degradation of adenosine may be
beneficial in the preventing of aortic valve inflammation, by
the retention of immunomodulatory adenosine.
The next step was to investigate, whether the aortic valve
decellularization process affects the activities of extracellular
nucleotide metabolism, what is important in terms of valvular
prostheses adaptation. Two decellularization techniques were
compared. It was revealed that the rate of ATP hydrolysis on
Fig. 1 Adenosine triphosphate (ATP) degrading capacity is increased on
the aortic valve surface as compared to the vessel surface. ATP
concentration during test (a) and calculated degradation rate of ATP (b)
on the surface of porcine aorta and aortic valve leaflet during a 30-min
incubation with 50 μM ATP. Values represent mean ± SEM, n = 4;
*p< 0.05
Fig. 2 Adenosine monophosphate (AMP) degrading capacity is
increased on the aortic valve surface as compared to the vessel surface.
AMP concentration during test (a) and calculated degradation rate of
AMP (b) on the surface of porcine aorta and aortic valve leaflet during
a 30-min incubation with 50 μM AMP. Values represent mean ± SEM,
n= 4; **p< 0.01
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the surface of processed valves greatly differed from the na-
tive valves (Fig. 4). After decellularization in hypotonic solu-
tion, ATP hydrolysis was preserved on the surface of aortic
valve leaflets, whereas it was almost completely removed after
detergent decellularization. A 48-h incubation in Hank’s solu-
tion at 4 and 37 °C only slightly affected the rate of ATP
hydrolysis. Similarly, rate of adenosine production (AMP hy-
drolysis) was completely removed from detergent-
decellularized leaflets while it was maintained after hypotonic
lysis and 48-h incubation in Hank’s solution (Fig. 5). The
increase in the ATP degradation entails a reduction of its pro-
inflammatory properties, what seems to be beneficial in the
aortic valve regeneration. On the other hand, only detergent-
based decellularization technique seems to solve the problem
of remaining on the valve surface enzymes immunogenicity.
Adenosine deaminase activity was six-fold lower after
2 days of incubation, and both methods of decellularization
entirely removed its activity (Fig. 6). The reduced adenosine
deaminase activity in the control assay (after 2 days of incu-
bation) testifies to the fact that the data obtained from the
processed valve surface are not only a result of
decellularization. This may be due to the instability of the
enzyme activity or unstable adenosine deaminase anchoring
in the cell membrane.
Blocking the nucleoside transport by NBTI did not affect
the rates of substrate conversion (data not shown) indicating
that only extracellular adenosine metabolism took place.
Discussion
This study supports the concept of special role of extracellular
nucleotide metabolism on the surface of heart valves. Activi-
ties that convert ATP to AMP and further to adenosine in the
valve leaflets far exceeded those found in the aortic wall.
Furthermore, we demonstrated diverse effects of procedures
for decellularization of xenograft valves for implantation in
humans. Some preserved nucleotide degrading activities,
while others caused their complete loss. This could have im-
plications for processes directly related to valve longevity.
Altered concentrations of nucleotide metabolites will affect
their signaling mechanisms and in turn, may affect patholog-
ically significant processes such as thrombosis, inflammation,
and calcification and, ultimately, could have important impli-
cations for the durability of generated valve bioprostheses.
Many literature data confirm the efficiency of used
decellularization techniques, including hypotonic lysis
followed by nuclease digestion [15], which is patented as
Fig. 3 Adenosine degrading capacity is decreased on the aortic valve
surface as compared to the vessel surface. Adenosine concentration
during test (a) and calculated degradation rate of adenosine (b) on the
surface of porcine aorta and aortic valve leaflet during a 30-min
incubation with 50 μM adenosine. Values represent mean ± SEM, n= 4;
***p< 0.001
Fig. 4 Adenosine triphosphate (ATP) degradation rate is preserved on
the surface of the aortic valve processed by hypotonic lysis in contrast to
the native valve, while the detergent treatment completely removes this
activity. ATP concentration during test (a) and calculated degradation rate
of ATP (b) on the surface of native and processed porcine aortic valve
leaflets, during a 30-min incubation of valve leaflets with 50 μM ATP.
Values represent mean ± SEM, n= 8; *p< 0.05, **p < 0.01, ***p< 0.001
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Synergraft® [35]. The effectiveness of the second, detergent-
based technique has been repeatedly confirmed histologically
by, e.g., H&E staining and Mason’s trichrome, as well as by
electron microscopy, which indicated no cell nuclei and cellu-
lar components after decellularization protocol, but still pre-
served essential extracellular matrix proteins, such as collagen
and elastin [36]. Our previous results already demonstrated
the presence of enzymes activities engaged in extracellular
nucleotide metabolism in the aortic valve, which favored the
production and retention of extracellular adenosine [29, 37].
Our current data confirmed these alterations in valvular ecto-
enzyme activities that could play the important role in valve
pathology and its regeneration.
Porcine aortic valves leaflets decellularized by hypotonic lysis
followed by nuclease treatment and -irradiation maintain almost
intact activities of nucleotide-degrading ectonucleotidases. One
possible mechanism for such effect is retention of cell mem-
branes within decellularized valve scaffold. Preservation of
ectonucleotidases may affect processes that are relevant to
early and late valve function. Maintenance of ATP degradation
and adenosine production capacity could protect the valve
against inflammation/calcific degeneration by facilitation of
pro-calcific ATP removal and production of protective adenosine
[18]. Also, our unpublished data, obtained from the calcified and
non-calcified human aortic valves, demonstrate the
significant involvement of extracellular nucleotide catabolism
in control of the aortic valve pathology. Additionally,
literature data suggest protective properties of the extracellular
adenosine in the context of implant adaptation. Tuskamoto
et al. shown that deficiency of ecto-5′-nucleotidase (CD73)
causes enhanced graft-versus-host-disease (GVHD) severity
[38]. Both mutant CD73−/−mice, as well as mice with pharma-
cological blockade of CD73 were characterized by stronger
cytotoxicity, cell expansion, and increased proinflammatory cy-
tokine concentration. However, potential disadvantage that is
highlighted by retention of enzyme activities is an immune re-
sponse. Retention of active enzymes indicates retention of im-
munogenic proteins that constitutes an important risk of graft
rejection [39]. Conversely, the use of a detergent-based
decellularization protocol completely reduced of all ecto-
enzymes activities.While such valves are less likely to be immu-
nogenic, nonviable valves devoid of potentially protective
ectonucleotidases could be prone to degeneration and calcifica-
tion [40]. Optimizing valve preparation technology to
Fig. 5 Adenosine production rate is preserved on the surface of the aortic
valve processed by hypotonic lysis in contrast to the native valve, while
the detergent treatment completely removed this activity. Adenosine
concentration during test (a) and calculated production rate of
adenosine (b) on the surface of native and processed porcine aortic
valve leaflets, during a 30-min incubation of valve leaflets with 50 μM
AMP. Values represent mean ± SEM, n = 8; *p < 0.05, **p < 0.01,
***p< 0.001
Fig. 6 Inosine production rate is profoundly decreased on the surface of
the aortic valve after control incubation regarding to the native valve and
completely removed after decellularization. Inosine concentration during
test (a) and calculated production rate (b) of inosine on the surface of
native and processed porcine aortic valve leaflets, during a 30-min
incubation of valve leaflets with 50 μM adenosine. Values represent
mean ± SEM, n= 8; *p< 0.05, **p< 0.01, ***p < 0.001
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maintain or restore ATP degrading ecto-enzymes on the surface
of bioprostheses seems to be a promising solution to improve
their quality.
The optimal approach could be recellularization of entirely
decellularized valves to obtain an implantable bioengineered
construct that shows the benefit of healthy valvular tissue that
has the potential ability to regenerate or remodel during its
lifetime in vivo. The first recellularization concept involves
the implantation of decellularized heart valves, which will be
reseeded in vivo in the patient’s body. Clinical data from this
field revealed successful effects [41, 42]; nevertheless, others
have shown a failure of xenogenic scaffolds to reseed [39].
Alternatively, a second approach comprises precise
decellularization and elimination of all cellular remnants
followed by in vitro cells reseeding. Valvular endothelial cells
(VECs) and valvular interstitial cells (VICs) are needed for
reseeding. However, since these cells cannot be directly har-
vested, alternate cell populations are required. Attempts were
made to use venous endothelial cell, obtained after surgical
procedure [43, 44]. As terminally differentiated cell types,
endothelial cells demonstrated many advantages, such as an-
tithrombotic properties that are also provided by effectively
functioning extracellular nucleotide catabolism [45, 46].
Moreover, endothelium covers the collagen surface, which
could protect against possible immunogenic reactions. This
may be caused by cytoprotective effect of immunosuppressive
adenosine generated by endothelial ecto-enzymes [47, 48].
However, endothelial cell harvest and expansion in vitro are
slow. Endothelial cell reseeding procedures fail due to a weak-
ly adherent endothelium whose survival post implantation is
likely very limited. Another approach is to modify the
decellularized tissue with molecules that could capture circu-
lating endothelial progenitor cells to the surface of the valve
after implantation into the recipient. Moreover, the utilization
of adipose-derived cells deserves attention. Adipose-derived
stem cells (ADSCs) or stromal vascular fraction cells (AD-
SVF) [49] could be successful due to their relatively effective
isolation from lipoaspirate obtained through route liposuction
procedures and recorded ability to differentiate into various
cell lineages [50]. It is documented that ADSCs differentiate
into cells expressing markers characteristic for valvular inter-
stitial cells (fibroblast-like cells) [51], but extracellular nucle-
otide catabolism enzymes specific for these cells needs to be
investigated further. It seems that development of new
recellularization strategies based on adipose-derived cells, like
interstitial seeding techniques by injection of ADSCs directly
into the valve leaflet structure, could be promising to obtain a
bioprosthesis that closely resembles a native aortic heart valve
[50]. The other solution could be the application of the
methods used in the production of therapeutic proteins
such as genetic engineering including gene isolation or
modification which affect the reduction of enzyme immuno-
genicity and have a favorable effect on the bioprosthesis
adaptation [52, 53]. While these strategies are likely to provide
ultimate solution for optimal valve graft, optimizing xenograft
valve preparation strategy that takes into account nucleotide
metabolic mechanisms may provide good intermediate solution.
In conclusion, we have shown that extracellular adenine
nucleotide catabolism operates at highest rates on the aortic
heart valve surface. Decellularization techniques used in xe-
nograft preparation affects this process in different ways.
Some methods preserve capability to degrade ATP to adeno-
sine while others completely remove these activities. We as-
sume that retention of nucleotide degrading capacity protects
valves from thrombosis, inflammation and calcification.
Therefore, the presence of extracellular nucleotide metabo-
lism enzymes on the valve prostheses is a potential approach
for improvement of the valve graft quality. However, this con-
cept requires further studies.
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